lunglow pt
face major catalyst read-out estim
occur sometim march-april time frame success mpf
benefit epa keytruda least month melanoma import first indic
ido nsclc key due market potenti io-chemo combin
deliv impress number nsclc independ express
seen recent result impow see higher
hurdl nsclc epa consequ lower probabl success
previous lower ep estim pt base
publish research believ nsclc treatment select primarili driven
nsclc largest cancer indic model un-risk-adjust peak
epa sale nsclc vs melanoma io-chemo combin deliv
impress result nsclc independ statu seen recent
result impow run two trial
nsclc
studi recent diagnos nsclc patient ask particip select
treatment prefer compar randomli gener option benefit
administr improv strongest decis factor
weigh especi fatigu come grade sever
conclud key nsclc epa keytruda chemo combo watch
believ nsclc preferenti treat aggress regimen
increas base studi conduct make keytruda
chemo hurdl month mpf exhibit nsclc all-com
base recent announc lower probabl success
epa nsclc previous
melanoma expect second interim analysi march-april
exhibit base trial design believ could posit
combin epa keytruda show increas benefit median
monotherapi month review recent data melanoma ido
like compet base superior toler
believ binari event melanoma difficult predict
due limit data avail remain perform rate nsclc io treatment
option increas need understand ido
regimen fit evolv treatment option data
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur appendix
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig partner candid baricitinib oral
therapi ra face signific us regulatori delay
may drive revenu upsid eventu deep
promis pipelin includ epacadostat combin
keytruda divers pipelin driven take-over
specul lead valuat premium fair market
valuat view
activ epacadostat combin
nsclc demonstr phase studi
regulatori approv launch baricitinib
multipl phase studi epacadostat
variou tumor type combin antibodi
result phase studi
epacadostat keytruda melanoma
approv olumi ra us
posit differenti epacadostat ido activ
combin checkpoint
differenti baricitinib label xeljanz tofacitinib
synergi novel indic
greater expect advanc pipelin asset
competit landscap io limit epacadostat ultim
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could
peak us includ peak royalti ex-u sale see iclusig olumi smaller contributor
revenu estim epacadostat sale advanc melanoma nsclc reach non-risk adjust peak
employ risk adjust olumi epacadostat melanoma nsclc tumor type
key known downsid risk price target clinic develop risk regulatori risk epacadostat addit risk come
build commerci infrastructur indic higher anticip competit ido inhibitor upsid
risk includ acquisit signific premium better expect clinic data epacadostat drug pipelin
bar nsclc rise chemo leader
chemo combin nsclc gain traction follow
acceler approv keytruda chemo may base
announc recent confirmatori trial met primari endpoint
os cement leadership posit treatment option outsid
epiderm growth factor receptor egfr anaplast lymphoma kinas posit
tumor roch posit impow readout tecentriq avastin chemo paclitaxel
carboplatin data data esmo show percent reduc risk
compar avastin chemo control arm ci
run two trial nsclc epacadostat keytruda
epacadostat keytruda chemo believ nsclc
preferenti treat aggress regimen increas base studi
conduct uk exhibit believ make keytruda chemo hurdl
month mpf nsclc all-com base newer strong result
lower probabl success epa nsclc previous
exhibit nsclc melanoma forecast nsclc larger opportun ido
exhibit keytruda chemo combo prior acceler approv may nsclc
recent achiev primari endpoint os believ nsclc
aggress treatment import make keytruda chemo hurdl clear
tripl combin epacadostat keytruda chemo
epacadostat sale carboplatin/pemetrexedepacadostat keytrudaepacadostat keytrudalin line prior comersorr dcr vs chemo grade vs vs nejm lancet compani inform
exhibit self-report patient prefer uk show import
improv select therapi conjoint analysi reveal benefit weight
side effect side effect becom decid factor sever mild grade
exhibit opco timelin estim expect second interim analysi
march-april base
need show month benefit view
low visibl perform control/act arm
base trial design believ could success
combin epa keytruda show increas benefit median keytruda
monotherapi month base estim observ event
alpha use rang
open-label uncontrol investig review trial epacadostat
combin keytruda deliv median advanc melanoma
mainli month impress orr separ studi keytruda
monotherapi treatment orr median
howev time somewhat concern epacadostat decreas cr
treatment-na melanoma patient sinc esmo cr compar
latest data cr cr decreas significantli cr
patient ad sinc esmo although like patient may simpli
requir follow-up achiev cr
efficaci data present esmo base investig review
hand histor control data compar data keynote-
central review separ believ on-going studi also
central review fact make compar across trial keynote-
even difficult assess ad benefit epa keytruda combin vs
keytruda alon addit earli read data show high
subsequ decreas data matur
estim aug-sep estim mar-apr postedfirst patient dosedeu trial detail postedcomplet enrol eventsfin analysi estim primari complet date os eventsestim studi complet datesourc oppenheim co estim clinicaltri gov compani informationopco trial modeltimeest enrol assum linear estimate patient trialest event observ per monthest cummul eventsest time analysistim point month keytruda keytruda esmo oppenheim co estim project curvesourc esmo oppenheim co estimatesev assumpt patient trialest event observ per monthest cummul
exhibit epacadostat data must achiev month improv mpf vs
keytruda monotherapi stop base estim point variabl
data matur associ risk predict
exhibit opco estim trial outcom base efficaci believ epa keytruda must
show month mpf benefit keytruda monotherapi stop
keytrudaepacadostat keytrudaepacadostat keytrudakeytrudakeytrudakeytrudalin therapyal line therapi cohortstudyesmo investg investg investg ci ci hrmo hrdurat respons score score score score score score tabl endpoint perform
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
thousand except per share
olumi eu
jakafi essenti thrombocythemia et
jakafi gvhd
probabl success
probabl success
probabl success
epacadostat tumor sale
probabl success
probabl success
rest pipelin
probabl success
mileston contract research
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
